New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

31

Mayo Clinic Launches Joint Ventures to Create and Commercialize AI Diagnostic Tools

Mayo Clinic launched two new tech venture companies designed to harness artificial intelligence (AI) and medical algorithms and create “software as medical devices” that clinicians can use to improve treatment across different diseases. 

33

Healthcare collapse imminent, Brazil’s Sao Paulo warns, as Covid-19 cases surge

Brazil’s richest and most populous state, Sao Paulo, warned its ability to care for seriously ill Covid-19 patients was on the verge of collapse as it ran perilously low on key drugs, according to a letter to the federal government seen by the Folha de Sao Paulo newspaper.

34

Elderly show similar antibody response to first dose of AstraZeneca, Pfizer Covid-19 shots: UK study

The first study to directly compare immune reactions between Pfizer’s and AstraZeneca’s Covid-19 vaccines found strong and broadly similar antibody responses in over-80-year-olds after a first dose of either shot, scientists said on April 14.

36

U.S. CDC to weigh rare clot risk with J&J’s Covid-19 vaccine as use paused

A U.S. health advisory panel on April 14 is set to review six reported cases of rare blood clots in women who received Johnson & Johnson’s Covid-19 vaccine one day after federal regulators paused the use of the shot to assess the issue.

38

AstraZeneca’s drug Tagrisso gets China nod for early lung cancer

AstraZeneca Plc said on April 14 that China’s health regulator expanded the use of Tagrisso, the British drugmaker’s lung cancer treatment, in patients with a type of lung cancer when diagnosed at an early stage.

39

U.S. FDA Grants Accelerated Approval to Trodelvy for Treatment of Metastatic Urothelial Cancer

The U.S. Food and Drug Administration granted accelerated approval of Gilead Sciences Inc.’s Trodelvy (sacituzumab govitecan-hziy) for use in adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 or a programmed death-ligand 1 inhibitor.